First National Bank of Omaha lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) by 26.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,371 shares of the specialty pharmaceutical company's stock after selling 5,805 shares during the quarter. First National Bank of Omaha's holdings in Supernus Pharmaceuticals were worth $529,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SUPN. Woodline Partners LP purchased a new stake in Supernus Pharmaceuticals in the 1st quarter valued at $15,689,000. Stephens Investment Management Group LLC raised its position in Supernus Pharmaceuticals by 27.2% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company's stock valued at $46,014,000 after purchasing an additional 337,902 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Supernus Pharmaceuticals by 108.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company's stock valued at $17,779,000 after purchasing an additional 285,737 shares during the last quarter. GW&K Investment Management LLC raised its position in Supernus Pharmaceuticals by 13.0% in the 4th quarter. GW&K Investment Management LLC now owns 1,836,466 shares of the specialty pharmaceutical company's stock valued at $53,551,000 after purchasing an additional 210,976 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its position in Supernus Pharmaceuticals by 17.7% in the 4th quarter. Epoch Investment Partners Inc. now owns 458,155 shares of the specialty pharmaceutical company's stock valued at $13,360,000 after purchasing an additional 68,750 shares during the last quarter. Hedge funds and other institutional investors own 99.81% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on SUPN. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 2nd. Piper Sandler upped their price objective on shares of Supernus Pharmaceuticals to $38.00 in a research report on Tuesday, September 6th.

Insider Transactions at Supernus Pharmaceuticals

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $34.90 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of 34.55 and a beta of 1.01. Supernus Pharmaceuticals, Inc. has a one year low of $24.95 and a one year high of $36.08. The firm has a fifty day moving average of $32.64 and a two-hundred day moving average of $30.49.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.15). Supernus Pharmaceuticals had a return on equity of 6.98% and a net margin of 9.12%. The company had revenue of $170.10 million for the quarter, compared to analyst estimates of $164.23 million. During the same period last year, the company earned $0.43 earnings per share. The business's revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.51 earnings per share for the current year.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

See Also

• Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
• 3 Banks Worth Considering For Q4
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week
• MarketBeat: Week in Review 9/12 – 9/16

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.